Can a more intense chemo regimen beat aggressive lymphoma?
NCT ID NCT07663175
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review of past data, no new drugs or tests are being given.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CARMEN regimen (intensified chemotherapy)
What this could lead to
If successful, this study could help identify whether intensified chemotherapy improves survival and remission rates for patients with aggressive B-cell lymphomas with MYC rearrangement.
What could go wrong
This is a retrospective observational study, not a controlled trial, so results may be influenced by selection bias. The findings will need confirmation in prospective studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Ospedale San Raffaele
Milan, Italy, 20132, Italy